Clinical significance of BRAF mutations in metastatic melanoma
- PMID: 15613230
- PMCID: PMC544849
- DOI: 10.1186/1479-5876-2-46
Clinical significance of BRAF mutations in metastatic melanoma
Abstract
Forty to eighty percent of melanoma tumors have activating mutations in BRAF although the clinical importance of these mutations is not clear. We previously reported an analysis of BRAF mutations in metastatic melanoma samples from 68 patients. In this study, we correlated patient baseline characteristics, prognostic factors, and/or clinical outcomes with the presence of BRAF mutations. No significant differences were observed in age, gender, location of primary melanoma, stage at the diagnosis, and depth of primary tumor between patients with and without BRAF mutations. Melanomas harboring BRAF mutations were more likely to metastasize to liver (P = 0.02) and to metastasize to multiple organs (P = 0.048). Neither time to progression to stage IV nor overall survival were associated with BRAF mutations. In conclusion, we observed no significant differences in clinical characteristics or outcomes between melanomas with or without BRAF mutations. Although there was an increased frequency of liver metastasis and tendency to metastasize to multiple organs in tumors with BRAF mutations, there was no detectable effect on survival. Future prospective studies should include analysis of whether BRAF mutations in melanoma tumors correlate with an increased tendency to metastasize to liver or to multiple organs.
Similar articles
-
Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.Br J Dermatol. 2013 Apr;168(4):708-16. doi: 10.1111/bjd.12140. Br J Dermatol. 2013. PMID: 23528057
-
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343559
-
Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.Ann Surg Oncol. 2012 Dec;19(13):4314-21. doi: 10.1245/s10434-012-2457-5. Epub 2012 Jul 7. Ann Surg Oncol. 2012. PMID: 22772867 Clinical Trial.
-
BRAF mutations in metastatic melanoma: a possible association with clinical outcome.Clin Cancer Res. 2003 Aug 15;9(9):3362-8. Clin Cancer Res. 2003. PMID: 12960123
-
BRAF somatic mutations in malignant melanoma and melanocytic naevi.Melanoma Res. 2006 Apr;16(2):97-103. doi: 10.1097/01.cmr.0000215035.38436.87. Melanoma Res. 2006. PMID: 16567964 Review.
Cited by
-
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.BMC Cancer. 2017 Aug 10;17(1):536. doi: 10.1186/s12885-017-3529-5. BMC Cancer. 2017. PMID: 28797232 Free PMC article.
-
Improving melanoma classification by integrating genetic and morphologic features.PLoS Med. 2008 Jun 3;5(6):e120. doi: 10.1371/journal.pmed.0050120. PLoS Med. 2008. PMID: 18532874 Free PMC article.
-
The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy.Med Oncol. 2015 Jan;32(1):440. doi: 10.1007/s12032-014-0440-7. Epub 2014 Dec 14. Med Oncol. 2015. PMID: 25502087
-
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.Clin Cancer Res. 2007 Apr 1;13(7):2068-74. doi: 10.1158/1078-0432.CCR-06-2120. Clin Cancer Res. 2007. PMID: 17404088 Free PMC article.
-
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.Br J Cancer. 2009 Nov 17;101(10):1724-30. doi: 10.1038/sj.bjc.6605371. Epub 2009 Oct 27. Br J Cancer. 2009. PMID: 19861964 Free PMC article. Clinical Trial.
References
-
- Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, Arbiser JL. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res. 2002;8:3728–3733. - PubMed
-
- Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003;63:756–759. - PubMed
-
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. doi: 10.1038/nature00766. - DOI - PubMed
-
- Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS Mutations in Human Lung Cancer and Melanoma. Cancer Res. 2002;62:6997–7000. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials